Australia’s PBS Lists Four Adalimumab Biosimilars
‘A-Flag’ Allows Substitution For Humira As Well As Between Biosimilars
Four different biosimilar versions of Humira will be listed on Australia’s PBS from the start of April, with the country’s “a-flagging” mechanism allowing substitution for the brand and between adalimumab biosimilars.
You may also be interested in...
Enbrel (etanercept) originator Pfizer has filed suit in Australia over the sale of Samsung Bioepis’ rival Brenzys biosimilar. It alleges that it has “suffered, and will continue to suffer, substantial loss and damage.”
At its debut year-end financial earnings call, Organon spoke in further detail about the impending launch of Humira biosimilars, as well as its desire to continue growing its portfolio.
AbbVie is spreading confusion among Australian doctors and patients with anti-competitive materials designed to fend off biosimilar adalimumab competition to Humira, according to a local biosimilars industry association.